Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17822617 | 1.00 | CA1 (0.56) | CA1CA2CA9 | |
| SCHEMBL15694522 | 1.00 | CA1 (0.56) | CA1CA2CA9 | |
| SCHEMBL20457638 | 1.00 | CA1 (0.56) | CA1CA2CA9 | |
| SCHEMBL26457815 | 0.82 | CA2 (0.64) | CA1CA2CA9 | |
| SCHEMBL1847432 | 0.82 | CA2 (0.64) | CA1CA2CA9 | |
| SCHEMBL27174720 | 0.82 | CA2 (0.64) | CA1CA2CA9 | |
| SCHEMBL14441192 | 0.82 | CA2 (0.64) | CA1CA2CA9 | |
| SCHEMBL16307847 | 0.82 | CA2 (0.64) | CA1CA2CA9 | |
| SCHEMBL10883648 | 0.82 | CA2 (0.64) | CA1CA2CA9 | |
| SCHEMBL15254185 | 0.82 | CA2 (0.64) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187759-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-11692005-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210155652-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2021-05-27 | — | — | US | disclosed |
| US-20200223860-A1 | THE TOTAL SYNTHESIS OF GLUCOSEPANE AND RELATED CHEMICAL REACTIONS, COMPOUNDS AND COMPOSITIONS AND OBTAINED THEREFROM AND METHODS OF TREATMENT | UNIV YALE (US) | 2020-07-16 | — | — | US | disclosed |
| US-7906460-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER (US) | 2011-03-15 | — | — | US | disclosed |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-08-02 | — | — | US | disclosed |
| US-7122359-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-17 | — | — | US | disclosed |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-03-20 | — | — | US | disclosed |
| US-4078139-A | Process for deoxygenating secondary alcohols | SCHERING CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155652-A1 | TLR7 AGONISTS | TLR7, TLR1, TLR9 | CA1 4872/4885CA2 4796/4885CA9 4617/4885 |
| US-20200223860-A1 | THE TOTAL SYNTHESIS OF GLUCOSEPANE AND RELATED CHEMICAL REACTIONS, COMPOUNDS AND COMPOSITIONS AND OBTAINED THEREFROM AND METHODS OF TREATMENT | PTMS, AGER, GALE | CA1 4847/4885CA2 4715/4885CA9 4766/4885 |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | PNP, NUDT14, ENTPD5 | CA1 4383/4885CA2 3438/4885CA9 3993/4885 |
| US-12187759-B2 | TLR7 agonists | TLR7, TLR1, TLR9 | CA1 4872/4885CA2 4796/4885CA9 4617/4885 |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | PNP, NUDT14, NUDT5 | CA1 4342/4885CA2 3133/4885CA9 3963/4885 |
| US-11692005-B2 | TLR7 agonists | TLR7, TLR1, TLR9 | CA1 4872/4885CA2 4796/4885CA9 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.